Early breast cancer patients | ||||||
---|---|---|---|---|---|---|
 | HER2 primary | ER primary | PR primary | HER2in + HER2ext + CK+ | HER2in + HER2ext-CK+ | HER2in-HER2ext-CK+ |
1 | + | + | + | 0 | 0 | 2 |
2 | - | + | + | 0 | 0 | 1 |
3 | - | + | + | 1 | 0 | 0 |
4 | + | - | + | 0 | 0 | 1 |
5 | - | + | + | 0 | 0 | 1 |
6 | - | + | - | 1 | 3 | 0 |
7 | - | - | + | 1 | 0 | 4 |
8 | - | Â | Â | 0 | 0 | 1 |
9 | - | + | + | 1 | 0 | 0 |
10 | - | + | + | 2 | 0 | 0 |
11 | - | + | + | 0 | 0 | 1 |
12 | - | + | + | 2 | 0 | 0 |
13 | - | + | + | 9 | 4 | 0 |
14 | + | Â | Â | 2 | 0 | 0 |
15 | - | Â | Â | 0 | 0 | 2 |
16 | - | + | + | 3 | 0 | 0 |
17 | - | - | + | 0 | 0 | 1 |
18 | + | + | + | 1 | 0 | 0 |
 |  |  |  | First-line metastatic breast cancer patients | ||
 | HER2 primary | ER primary | PR primary | HER2in + HER2ext + CK+ | HER2in + HER2ext-CK+ | HER2in-HER2ext-CK+ |
1 | + | Â | Â | 5 | 0 | 0 |
2 | - | + | - | 0 | 1 | 2 |
3 | - | + | + | 100 | 0 | 0 |
4 | + | - | - | 0 | 0 | 1 |
5 | - | + | - | 0 | 0 | 1 |
6 | - | + | + | 1 | 0 | 0 |
7 | + | - | - | 1 | 1 | 0 |
8 | - | - | + | 0 | 0 | 1 |
9 | + | + | + | 1 | 0 | 0 |
10 | - | + | + | 0 | 0 | 8 |
11 | - | + | + | 2 | 1 | 1 |
12 | + | + | + | 0 | 2 | 1 |
13 | - | + | + | 0 | 0 | 1 |
14 | Â | Â | Â | 0 | 1 | 1 |
15 | + | - | - | 1 | 0 | 0 |
16 | Â | Â | Â | 0 | 0 | 1 |
17 | + | - | - | 1 | 0 | 0 |
18 | + | - | - | 0 | 1 | 0 |
19 | + | - | - | 0 | 0 | 1 |
20 | - | + | + | 2 | 1 | 1 |
21 | - | - | - | 0 | 1 | 1 |
22 | Â | + | + | 3 | 2 | 20 |
23 | + | + | + | 0 | 0 | 2 |